Hikma Pharmaceuticals logo

HIK - Hikma Pharmaceuticals News Story

2650p 11.0  0.4%

Last Trade - 18/09/20

Sector
Healthcare
Size
Large Cap
Market Cap £6.11bn
Enterprise Value £6.50bn
Revenue £1.77bn
Position in Universe 133rd / 1807

UK's Hikma starts manufacturing COVID-19 treatment remdesivir for Gilead

Fri 7th August, 2020 9:00am
Aug 7 (Reuters) - Hikma Pharmaceuticals  HIK.L  has started
manufacturing remdesivir, an approved treatment for COVID-19
from U.S.-based Gilead  GILD.O , for an undisclosed amount at
its facility in Portugal, the British company's chief executive
officer said.
    The company will supply the first batches of the antiviral
drug "soon," and Gilead is expected to distribute the treatment,
which was the first to be greenlit for the illness caused by the
new coronavirus. 
    "The terms of the deal are confidential, we are simply a
contract manufacturer for Gilead - they order products from us
as they expect the sales to be," CEO Siggi Olafsson told Reuters
on Friday. 
    

 (Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun
Koyyur)
 ((Pushkala.A@thomsonreuters.com; Twitter: @pullthekart; within
UK: +44 20 7542 1810, outside UK: +91 80 6182 2600; Mobile: +91
852 751 3793 ;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.